{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:13:11Z","timestamp":1788369191176,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergies and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI77512"],"award-info":[{"award-number":["R01AI77512"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:p>Time to symptom elimination is a statistically inefficient end point for respiratory virus trials that ignores the most clinically relevant time points. Alternatively, clearance slope and area under the curve may efficiently capture improvement early during treatment when symptoms are most severe.<\/jats:p>","DOI":"10.1093\/infdis\/jiag148","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:48:24Z","timestamp":1772628504000},"page":"168-171","source":"Crossref","is-referenced-by-count":0,"title":["Is it \u201cTime to Eliminate\u201d Time to Elimination of Symptoms as a Primary Trial End Point for Drugs Targeting Respiratory Viruses?"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-1621","authenticated-orcid":false,"given":"Joshua T","family":"Schiffer","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-3834","authenticated-orcid":false,"given":"Shadisadat","family":"Esmaeili","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-0203","authenticated-orcid":false,"given":"Katherine","family":"Owens","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-7984","authenticated-orcid":false,"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-9470","authenticated-orcid":false,"given":"Alpana","family":"Waghmare","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Pediatrics, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Center for Clinical and Translational Research, Seattle Children's Research Institute , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2026090212215944000_jiag148-B1","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/infdis\/jiad559","article-title":"The annual economic burden of respiratory syncytial virus in adults in the United States","volume":"230","author":"Carrico","year":"2024","journal-title":"J Infect Dis"},{"key":"2026090212215944000_jiag148-B2","doi-asserted-by":"crossref","first-page":"e2536635","DOI":"10.1001\/jamanetworkopen.2025.36635","article-title":"Enduring outcomes of COVID-19 work absences on the US labor market","volume":"8","author":"Dennett","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026090212215944000_jiag148-B3","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2468-2667(23)00079-8","article-title":"Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform","volume":"8","author":"Nab","year":"2023","journal-title":"Lancet Public Health"},{"key":"2026090212215944000_jiag148-B4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090212215944000_jiag148-B5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090212215944000_jiag148-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090212215944000_jiag148-B7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"issue":":","key":"2026090212215944000_jiag148-B8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(25)00238-5","article-title":"Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study","volume":"25","author":"Ogbuagu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026090212215944000_jiag148-B9","doi-asserted-by":"crossref","first-page":"e192052","DOI":"10.1172\/JCI192052","article-title":"Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2","volume":"135","author":"Esmaeili","year":"2025","journal-title":"J Clin Invest"},{"key":"2026090212215944000_jiag148-B10","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1038\/s41467-024-49458-9","article-title":"A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy","volume":"15","author":"Esmaeili","year":"2024","journal-title":"Nat Commun"},{"key":"2026090212215944000_jiag148-B11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"2026090212215944000_jiag148-B12","doi-asserted-by":"crossref","first-page":"e2354991","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026090212215944000_jiag148-B13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/cid\/ciaf029","article-title":"Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial","volume":"80","author":"Luetkemeyer","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026090212215944000_jiag148-B14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1473-3099(25)00482-7","article-title":"Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"26","author":"Schilling","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026090212215944000_jiag148-B15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090212215944000_jiag148-B16","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026090212215944000_jiag148-B17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090212215944000_jiag148-B18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"2026090212215944000_jiag148-B19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026090212215944000_jiag148-B20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial","volume":"25","author":"Weinstein","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026090212215944000_jiag148-B21","doi-asserted-by":"crossref","first-page":"e63537","DOI":"10.7554\/eLife.63537","article-title":"Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events","volume":"10","author":"Goyal","year":"2021","journal-title":"Elife"},{"key":"2026090212215944000_jiag148-B22","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1093\/infdis\/jiaf442","article-title":"Accurate measurement of viral clearance in early phase antiviral studies in COVID-19","volume":"233","author":"Wongnak","year":"2025","journal-title":"J Infect Dis"},{"key":"2026090212215944000_jiag148-B23","author":"Food and Drug Administration"},{"key":"2026090212215944000_jiag148-B24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3201\/eid3002.230835","article-title":"Public health impact of paxlovid as treatment for COVID-19, United States","volume":"30","author":"Bai","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026090212215944000_jiag148-B25","doi-asserted-by":"crossref","first-page":"e235044","DOI":"10.1001\/jamahealthforum.2023.5044","article-title":"Clinical risk and outpatient therapy utilization for COVID-19 in the Medicare population","volume":"5","author":"Wilcock","year":"2024","journal-title":"JAMA Health Forum"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag148\/67260993\/jiag148.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/168\/67260993\/jiag148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/168\/67260993\/jiag148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:22:04Z","timestamp":1788366124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/2\/168\/8509492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,7]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag148","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,3,7]]}}}